This new patent relates to a method of testing a drug or novel compound to determine its propensity for inducing cholestasis, a common toxic side effect of certain drugs, by looking at its impact on a set of indicator genes, or biomarkers.
This biomarker set is one of dozens from the company’s proprietary library of Drug Signatures, which have been derived from DrugMatrix, the reference database linking gene expression profiles of over 630 drugs to results from traditional preclinical pharmacology, safety, and toxicity tests.
James Karis, president and CEO of Entelos, said: “We are pleased to add this new patent to our growing portfolio of patents that strengthen our leadership position in both disease simulation and predictive technologies focused on safety and toxicity testing.”